Biocon Ltd, in collaboration with its European partner Zentiva, has obtained decentralised procedure approval in the European Union for their complex formulation, Liraglutide, which is used to manage diabetes and support weight management.
The approval covers generic versions of Victoza, indicated for treating Type-2 Diabetes, and Saxenda, used for weight management, Biocon Ltd stated in a regulatory filing.
Victoza and Saxenda are trademarks owned by Novo Nordisk.
A long-standing challenge in the GST appeals process, relating to mandatory pre-deposit payments, has finally been addressed with the introduction of Form GST DRC-03A, offering relief to taxpayers who were earlier caught...
Shares of The Trade Desk fell sharply by more than 9% in recent trading, following reports of mounting concerns around its platform performance and advertiser confidence. The decline comes after French advertising...
BENGALURU: The wait is finally over for Indian metalheads, where the platform is set for Opeth to Return to India After 7 Years. After months of speculation and a "mysterious" ticket link...
The 98th Academy Awards (Oscars 2026) brought together the biggest names in global cinema to celebrate the finest achievements in filmmaking. The ceremony took place on March 15, 2026, at the Dolby...
Industry Insights Magazine delivers expert analysis, trends, and startup stories across sectors like Finance, Healthcare, Manufacturing, and Real Estate. With curated interviews, case studies, and reports, we empower professionals and entrepreneurs with actionable insights, helping them navigate change, discover opportunities, and lead confidently in today’s dynamic business landscape.
Discussion about this post